In December 2024, Dutch Pharming Technologies announced a recommended cash offer to the shareholders of Abliva to tender all their shares in Abliva to Pharming at a price of SEK 0.45 in cash per share. One of the original conditions for completing the offer was to reach over 90% ownership.

Pharming has now chosen to waive this requirement and thus completes the acquisition based on the current acceptance level of 87.7%. In order to give remaining shareholders the opportunity to accept the offer, the acceptance period has been extended until 20 February 2025.

The Board of Directors of Abliva has unanimously recommended that the shareholders of Abliva accept the public cash offer.

There are currently no decisions on any changes that may impact Abliva’s employees and management, including their terms of employment, Abliva’s organization or operational sites.

Mitochondrial diseases

Abliva focuses on developing drugs for the treatment of mitochondrial diseases. The company is currently conducting a phase II study with lead candidate KL1333, which is being evaluated as a treatment for mitochondrial diseases linked to mutations in mitochondrial DNA.

Related article

How cells manage oxygen

The 2019 Nobel Prize in Physiology or Medicine was awarded to William G. Kaelin Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza for revealing the mechanism of one of life’s most essential adaptive processes.